Unique associated Kaposi's sarcoma virus sequences and uses thereof
AssigneeThe Trustees of Columbia University in the City of New York
InventorsYuan Chang, Patrick S. Moore
Life of this patent
Estimating the term…
Abstract
This invention provides an isolated peptide encoded by a nucleic acid which is at least 30 nucleotides in length and has a sequence which uniquely defines a herpesvirus associated with Kaposis' sarcoma, which herpesvirus is present in and recoverable from the HBL-6 cell line (ATCC Accession No. CRL 11762).
Claims10
1-42. (canceled)
An antibody which specifically binds to a polypeptide of a Kaposi's sarcoma-associated herpesvirus.
An isolated DNA molecule which is at least 30 nucleotides in length and uniquely defines a herpesvirus associated with Kaposi's sarcoma.
An isolated peptide encoded by at least, a portion of a nucleic acid molecule with a sequence as set forth in (SEQ ID NOs:
- 1-37)
A method of vaccinating a subject against Kaposi's sarcoma, comprising administering to the subject an effective amount of the peptide of claim 17, and a suitable acceptable carrier, thereby vaccinating the subject.
A method of immunizing a subject against a disease caused by the herpesvirus associated with Kaposi's sarcoma which comprises administering to the subject an effective immunizing dose of the vaccine of claim 12.
A method for preventing the development or transmission of herpesvirus associated Kaposi's sarcoma in a subject by treating a subject with Kaposi's sarcoma (KS) comprising administering to the subject having a human herpesvirus-associated KS a pharmaceutically effective amount of an antiviral agent in a pharmaceutically acceptable carrier, wherein the agent is effective to preventing the development or transmission of the KS-associated human herpes virus of claim 12.
Dependencies are inferred from the claim text.